Atlas Trials

SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer

Clinical trial NCT07683221 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07683221
Sponsor
Shandong Cancer Hospital and Institute
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Cancer
Start date
2026-07-15
Primary completion
2029-07-15
Enrollment
47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.